Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 434

1.

An international registry of patients with plasminogen deficiency (HISTORY).

Shapiro AD, Menegatti M, Palla R, Boscarino M, Roberson C, Lanzi P, Bowen J, Nakar C, Janson IA, Peyvandi F.

Haematologica. 2020 Jan 30. pii: haematol.2019.241158. doi: 10.3324/haematol.2019.241158. [Epub ahead of print]

2.

Perceived well-being and mental health in haemophilia.

Negri L, Buzzi A, Aru AB, Cannavò A, Castegnaro C, Fasulo MR, Lassandro G, Rocino A, Santoro C, Sottilotta G, Giordano P, Mazzucconi MG, Mura R, Peyvandi F, Delle Fave A.

Psychol Health Med. 2020 Jan 26:1-11. doi: 10.1080/13548506.2020.1717556. [Epub ahead of print]

PMID:
31984755
3.

Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients.

Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Subramanian K, D'Souza F, Viswabandya A, Hoorfar H, Schwartz BA, Solomon C, Knaub S, Peyvandi F.

J Thromb Haemost. 2019 Dec 29. doi: 10.1111/jth.14727. [Epub ahead of print]

PMID:
31885190
4.

Novel variant in HPS3 gene in a patient with Hermansky Pudlak syndrome (HPS) type 3.

Lecchi A, La Marca S, Femia EA, Lenz A, Boeckelmann D, Artoni A, Peyvandi F, Zieger B.

Platelets. 2019 Dec 27:1-4. doi: 10.1080/09537104.2019.1704716. [Epub ahead of print]

PMID:
31880485
5.

High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.

Mancuso ME, Linari S, Santagostino E, Bartolozzi D, D'Ambrosio R, Borghi M, Lampertico P, Peyvandi F, Castaman G, Aghemo A.

Liver Int. 2019 Dec 26. doi: 10.1111/liv.14337. [Epub ahead of print]

PMID:
31876354
6.

Adult-Onset Still Disease After Human Herpesvirus 6 Infection in an Elderly Patient: A Case Report.

Rossio R, Colombo G, Piconi S, Peyvandi F.

J Clin Rheumatol. 2019 Nov 21. doi: 10.1097/RHU.0000000000001225. [Epub ahead of print] No abstract available.

PMID:
31809281
7.

Management of rare acquired bleeding disorders.

Menegatti M, Biguzzi E, Peyvandi F.

Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):80-87. doi: 10.1182/hematology.2019000066.

PMID:
31808848
8.

Procoagulant imbalance in preterm neonates detected by thrombin generation procedures.

Tripodi A, Raffaeli G, Scalambrino E, Padovan L, Clerici M, Chantarangkul V, Cavallaro G, Peyvandi F, Mosca F, Ghirardello S.

Thromb Res. 2020 Jan;185:96-101. doi: 10.1016/j.thromres.2019.11.013. Epub 2019 Nov 15.

PMID:
31786478
9.

Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.

Peri AM, Rossio R, Tafuri F, Benzecry V, Grancini A, Reda G, Bandera A, Peyvandi F.

Ann Hematol. 2019 Dec;98(12):2847-2849. doi: 10.1007/s00277-019-03837-1. Epub 2019 Nov 18. No abstract available.

PMID:
31741032
10.

Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban.

Tripodi A, Chantarangkul V, Padovan L, Clerici M, Scalambrino E, Peyvandi F.

J Thromb Thrombolysis. 2019 Nov 14. doi: 10.1007/s11239-019-01993-9. [Epub ahead of print]

PMID:
31728842
11.

Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil.

Fioredda F, Cappelli E, Mariani A, Beccaria A, Palmisani E, Grossi A, Ceccherini I, Venè R, Micalizzi C, Calvillo M, Pierri F, Mancini I, Peyvandi F, Corsolini F, Dufour C, Miano M.

Blood Adv. 2019 Nov 12;3(21):3432-3435. doi: 10.1182/bloodadvances.2019000575. No abstract available.

12.

Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease.

Paraboschi EM, Khera AV, Merlini PA, Gigante L, Peyvandi F, Chaffin M, Menegatti M, Busti F, Girelli D, Martinelli N, Olivieri O, Kathiresan S, Ardissino D, Asselta R, Duga S.

Haematologica. 2019 Nov 7. pii: haematol.2019.237750. doi: 10.3324/haematol.2019.237750. [Epub ahead of print]

13.

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F.

J Thromb Haemost. 2020 Feb;18(2):479-484. doi: 10.1111/jth.14679. Epub 2019 Dec 9.

PMID:
31691462
14.

The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age.

Agosti P, Mancini I, Artoni A, Ferrari B, Pontiggia S, Trisolini SM, Facchini L, Peyvandi F; Italian Group of TTP Investigators.

Thromb Res. 2019 Oct 22. pii: S0049-3848(19)30455-4. doi: 10.1016/j.thromres.2019.10.010. [Epub ahead of print]

PMID:
31685248
15.

Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity.

Valsecchi C, Mirabet M, Mancini I, Biganzoli M, Schiavone L, Faraudo S, Mane-Padros D, Giles D, Serra-Domenech J, Blanch S, Trisolini SM, Facchini L, Rinaldi E, Peyvandi F.

Thromb Haemost. 2019 Nov;119(11):1767-1772. doi: 10.1055/s-0039-1696718. Epub 2019 Oct 6.

16.

Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura.

Riva S, Mancini I, Maino A, Ferrari B, Artoni A, Agosti P, Peyvandi F.

Haematologica. 2019 Sep 26. pii: haematol.2019.226423. doi: 10.3324/haematol.2019.226423. [Epub ahead of print]

17.

Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register.

Rossio R, Ardoino I, Franchi C, Nobili A, Mannuccio Mannucci P, Peyvandi F; REPOSI Investigators.

Intern Emerg Med. 2019 Nov;14(8):1347-1352. doi: 10.1007/s11739-019-02178-1. Epub 2019 Aug 23. No abstract available.

PMID:
31444740
18.

Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis.

Sigon G, D'Ambrosio R, Clerici M, Pisano G, Chantarangkul V, Sollazzi R, Lombardi R, Peyvandi F, Lampertico P, Fargion S, Tripodi A, Fracanzani AL.

Liver Int. 2019 Dec;39(12):2309-2316. doi: 10.1111/liv.14213. Epub 2019 Aug 30.

PMID:
31419372
19.

Real-life experience in switching to new extended half-life products at European haemophilia centres.

Peyvandi F, Garagiola I, Boscarino M, Ryan A, Hermans C, Makris M.

Haemophilia. 2019 Nov;25(6):946-952. doi: 10.1111/hae.13834. Epub 2019 Aug 16.

PMID:
31418967
20.

International Society on Thrombosis and Haemostasis core curriculum project: Core competencies in laboratory thrombosis and hemostasis.

Moffat KA, Kiencke V, Blanco AN, McLintock C, Peyvandi F, de Maat MPM, Adams MJ, Angchaisuksiri P, Nair S, Tsuda H, Haddad M, Renné T, Clark RC, Ross MT.

J Thromb Haemost. 2019 Nov;17(11):1848-1859. doi: 10.1111/jth.14601. Epub 2019 Sep 5.

PMID:
31400072
21.

Profiling the mutational landscape of coagulation factor V deficiency.

Paraboschi EM, Menegatti M, Rimoldi V, Borhany M, Abdelwahab M, Gemmati D, Peyvandi F, Duga S, Asselta R.

Haematologica. 2019 Aug 8. pii: haematol.2019.232587. doi: 10.3324/haematol.2019.232587. [Epub ahead of print]

22.

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery: Reply.

Peyvandi F.

J Thromb Haemost. 2019 Aug;17(8):1405-1406. doi: 10.1111/jth.14545. No abstract available.

PMID:
31368219
23.

How we make an accurate diagnosis of von Willebrand disease.

Baronciani L, Peyvandi F.

Thromb Res. 2019 Jul 16. pii: S0049-3848(19)30293-2. doi: 10.1016/j.thromres.2019.07.010. [Epub ahead of print] Review.

PMID:
31353031
24.

Burden of mild haemophilia A: Systematic literature review.

Peyvandi F, Tavakkoli F, Frame D, Quinn J, Kim B, Lawal A, Lee MC, Wong WY.

Haemophilia. 2019 Sep;25(5):755-763. doi: 10.1111/hae.13777. Epub 2019 Jul 11.

25.

Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia.

Peyvandi F, Garagiola I.

Haemophilia. 2019 Sep;25(5):738-746. doi: 10.1111/hae.13816. Epub 2019 Jul 8. Review.

PMID:
31282050
26.

Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects.

De Cristofaro R, Sacco M, Lancellotti S, Berruti F, Garagiola I, Valsecchi C, Basso M, Di Stasio E, Peyvandi F.

TH Open. 2019 May 8;3(2):e123-e131. doi: 10.1055/s-0039-1688413. eCollection 2019 Apr.

27.

Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.

Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E.

Blood Rev. 2019 Nov;38:100572. doi: 10.1016/j.blre.2019.04.001. Epub 2019 Apr 3. Review.

28.

Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis.

Weyand AC, Grzegorski SJ, Rost MS, Lavik KI, Ferguson AC, Menegatti M, Richter CE, Asselta R, Duga S, Peyvandi F, Shavit JA.

Blood Adv. 2019 Jun 11;3(11):1670-1680. doi: 10.1182/bloodadvances.2018029066.

29.

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.

Oldenburg J, Hay CRM, Jiménez-Yuste V, Peyvandi F, Schved JF, Szamosi J, Winding B, Lethagen S.

BMJ Open. 2019 May 30;9(5):e028012. doi: 10.1136/bmjopen-2018-028012.

30.

Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A.

Novembrino C, Boscolo Anzoletti M, Mancuso ME, Shinohara S, Peyvandi F.

Haemophilia. 2019 May;25(3):521-526. doi: 10.1111/hae.13746. Epub 2019 May 2.

PMID:
31044485
31.

Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement.

Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F.

Haematologica. 2019 Aug;104(8):e380-e382. doi: 10.3324/haematol.2018.215129. Epub 2019 Mar 28. No abstract available.

32.

Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry.

Mancini I, Pontiggia S, Palla R, Artoni A, Valsecchi C, Ferrari B, Mikovic D, Peyvandi F; Italian Group of TTP Investigators.

Thromb Haemost. 2019 May;119(5):695-704. doi: 10.1055/s-0039-1679907. Epub 2019 Mar 12.

PMID:
30861548
33.

Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study.

Maino A, Algra A, Peyvandi F, Rosendaal FR, Siegerink B.

BMC Cardiovasc Disord. 2019 Mar 7;19(1):55. doi: 10.1186/s12872-019-1040-4.

34.

Complications of whole-exome sequencing for causal gene discovery in primary platelet secretion defects.

Gorski MM, Lecchi A, Femia EA, La Marca S, Cairo A, Pappalardo E, Lotta LA, Artoni A, Peyvandi F.

Haematologica. 2019 Oct;104(10):2084-2090. doi: 10.3324/haematol.2018.204990. Epub 2019 Feb 28.

35.

Understanding the Impact of Aberrant Splicing in Coagulation Factor V Deficiency.

Paraboschi EM, Menegatti M, Peyvandi F, Duga S, Asselta R.

Int J Mol Sci. 2019 Feb 20;20(4). pii: E910. doi: 10.3390/ijms20040910.

36.

Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura.

Ferrari B, Cairo A, Pagliari MT, Mancini I, Arcudi S, Peyvandi F.

J Thromb Haemost. 2019 Apr;17(4):666-669. doi: 10.1111/jth.14409. Epub 2019 Mar 6.

PMID:
30762934
37.

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB.

Blood Transfus. 2019 Sep;17(5):391-398. doi: 10.2450/2019.0183-18. Epub 2019 Feb 4.

38.

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Repessé Y, Costa C, Palla R, Moshai EF, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31. No abstract available.

39.

Body mass index reduction improves the baseline procoagulant imbalance of obese subjects.

Tripodi A, Primignani M, Badiali S, de Ruberto F, Granelli P, Tosetti G, Clerici M, Padovan L, Chantarangkul V, Scalambrino E, Peyvandi F.

J Thromb Thrombolysis. 2019 Jul;48(1):52-60. doi: 10.1007/s11239-019-01818-9.

PMID:
30701462
40.

Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series.

Arcudi S, Ferrari B, Pontiggia S, Tufano A, Artoni A, Mancini I, Peyvandi F.

J Thromb Haemost. 2019 Mar;17(3):492-498. doi: 10.1111/jth.14381. Epub 2019 Feb 25.

PMID:
30629316
41.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators.

N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.

42.

Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study.

Tripodi A, Chantarangkul V, Clerici M, Bader R, Anzoletti MB, Peyvandi F, Santagostino EM; PredicTGA Collaborators.

Thromb Res. 2019 Feb;174:84-87. doi: 10.1016/j.thromres.2018.12.007. Epub 2018 Dec 6. No abstract available.

PMID:
30579150
43.

Treatment of rare factor deficiencies other than hemophilia.

Menegatti M, Peyvandi F.

Blood. 2019 Jan 31;133(5):415-424. doi: 10.1182/blood-2018-06-820738. Epub 2018 Dec 17. Review.

PMID:
30559262
44.

Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Schelpe AS, Roose E, Joly BS, Pareyn I, Mancini I, Biganzoli M, Deckmyn H, Voorberg J, Fijnheer R, Peyvandi F, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

Haematologica. 2019 Jun;104(6):1268-1276. doi: 10.3324/haematol.2018.205666. Epub 2018 Dec 6.

45.

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.

Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S.

Haemophilia. 2019 Jan;25(1):33-44. doi: 10.1111/hae.13618. Epub 2018 Nov 14.

46.

Thromboelastometry. Reproducibility of duplicate measurement performed by the RoTem® device.

Scalambrino E, Padovan L, Clerici M, Chantarangkul V, Biliou S, Peyvandi F, Tripodi A.

Thromb Res. 2018 Dec;172:139-141. doi: 10.1016/j.thromres.2018.10.030. Epub 2018 Oct 31. No abstract available.

PMID:
30412836
47.

Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus.

Stufano F, Baronciani L, Biguzzi E, Cozzi G, Colpani P, Chisini M, Peyvandi F.

Haemophilia. 2019 Jan;25(1):e30-e32. doi: 10.1111/hae.13626. Epub 2018 Nov 8. No abstract available.

48.

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A.

J Thromb Haemost. 2019 Jan;17(1):52-62. doi: 10.1111/jth.14313. Epub 2018 Dec 20.

49.

Hemostatic abnormalities in patients with Ehlers-Danlos syndrome.

Artoni A, Bassotti A, Abbattista M, Marinelli B, Lecchi A, Gianniello F, Clerici M, Bucciarelli P, La Marca S, Peyvandi F, Martinelli I.

J Thromb Haemost. 2018 Dec;16(12):2425-2431. doi: 10.1111/jth.14310. Epub 2018 Nov 8.

PMID:
30312027
50.

Advances in the Treatment of Hemophilia: Implications for Laboratory Testing.

Tripodi A, Chantarangkul V, Novembrino C, Peyvandi F.

Clin Chem. 2019 Feb;65(2):254-262. doi: 10.1373/clinchem.2017.284356. Epub 2018 Oct 3. Review.

PMID:
30282700

Supplemental Content

Loading ...
Support Center